[ad_1]
Shanghai, Beijing, Hong Kong, July 4, 2021 /PRNewswire/ – Sperogenix (Shanghai) MedTech Co., Ltd. (“Sperogenix”), a subsidiary of Sperogenix Therapeutics (orphan drug development and commercialization platform company) China), has signed an exclusive license agreement with Abbisko Therapeutics Co., Ltd. (“Abbisko”), a Chinese biopharmaceutical company focused on innovative drug discovery and development, to jointly develop and commercialize the innovative drug ABSK021 for rare neurological diseases for indications field.
According to the agreement, Sperogenix will have the exclusive right to develop, manufacture and commercialize ABSK021 in mainland China China, Hong Kong Special Administrative Region and Macau Special Administrative Region (collectively referred to as the “Sperogenix Region”) are used for non-tumor rare neurological disease indications. Amyotrophic lateral sclerosis (ALS) will be the first indication developed by Sperogenix. Abbisko will receive advance payments and a series of milestone payments and royalties on annual net sales from Sperogenix, and reserves the right to all other regions and indications. Sperogenix will be responsible for the development of ABSK021 in ALS, including preclinical research, proof-of-concept clinical trials, key clinical trials and post-marketing research, as well as the registration and commercialization of the product in the Sperogenix region.
ABSK021 is an oral bioavailable, effective and selective colony stimulating factor 1 receptor (CSF-1R) antagonist. Phase Ib clinical trials on the safety, tolerability and pharmacokinetics of cancer patients…
The full story on Benzinga.com
[ad_2]
Source link
